Sign inCreate account

Report workspace tools

NCT03401060COMPLETEDanonymous

Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis

Sponsor

Source record

Assistance Publique - Hôpitaux de Paris

Phase

Source record

PHASE3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Osteoporosis associated with systemic mastocytosis

Indication / condition

AI-normalized

Osteoporosis

Intervention

Source record

Denosumab, Placebo

Source & freshness

Source record

NCT ID

NCT03401060

Original source

ClinicalTrials.gov

Source last updated

Mar 31, 2026

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03401060

Title

Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis

Sponsor

Assistance Publique - Hôpitaux de Paris

Status

COMPLETED

Phase

PHASE3

Condition raw

Osteoporosis

Condition normalized

Osteoporosis

Modality raw

Osteoporosis

Modality normalized

monoclonal antibody

Target raw

Osteoporosis associated with systemic mastocytosis

Target normalized

Osteoporosis associated with systemic mastocytosis

Interventions

Denosumab, Placebo

Public preview

Source record

This clinical trial evaluates the efficacy of Denosumab, an anti-RANKL monoclonal antibody, in improving bone mineral density (BMD) in patients with osteoporosis due to systemic mastocytosis. The study is sponsored by Assistance Publique - Hôpitaux de Paris and involves a randomized, double-blind design comparing Denosumab to a placebo over three years.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03401060

Status

COMPLETED

Phase

PHASE3

Sponsor

Assistance Publique - Hôpitaux de Paris

Executive brief

Investment-Ready Snapshot

This clinical trial evaluates the efficacy of Denosumab, an anti-RANKL monoclonal antibody, in improving bone mineral density (BMD) in patients with osteoporosis due to systemic mastocytosis. The study is sponsored by Assistance Publique - Hôpitaux de Paris and involves a randomized, double-blind design comparing Denosumab to a placebo over three years.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 31, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03401060

Indication

Osteoporosis

Modality

monoclonal antibody

Target

Osteoporosis associated with systemic mastocytosis

Intervention

Denosumab, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.